RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cancer; Fallopian Tube; Epithelial Ovarian Interventions: Drug: RC88 Sponsors: RemeGen Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Epithelial Cancer | Fallopian Tube Cancer | Ovarian Cancer | Ovaries | Peritoneal Cancer | Research